-
AbbVie Analyst Upgrades Stock To Outperform, Looks Forward To 2021
Monday, April 20, 2020 - 12:50pm | 413Read More...AbbVie Inc (NYSE: ABBV) shares already discount much of the risk emanating from the COVID-19 crisis, according to an analyst at RBC Capital Markets. The AbbVie Analyst Randall Stanicky upgraded AbbVie from Sector Perform to Outperform and increased the price target from $79 to $93. The AbbVie...
-
OptiNose's Q2 Results Reflect Strong Underlying Trends, RBC Says
Tuesday, August 13, 2019 - 3:45pm | 261Read More...OptiNose Inc’s (NASDAQ: OPTN) XHANCE nasal spray continued to exhibit encouraging trends in the second quarter, suggesting that the company's launch is progressing on track, according to RBC Capital Markets. The Analyst RBC Capital Markets’ Randall Stanicky maintained an...
-
Analysts Positive On Insys Ahead Of 2019 Pipeline Catalysts
Friday, March 8, 2019 - 11:38am | 480Read More...Insys Therapeutics Inc (NASDAQ: INSY), which specializes in painkillers and synthetic cannabinoid drugs, reported Thursday after the close with a sharp decline in revenue and a wider-than-expected loss in the fourth quarter. The Analysts Janney analyst Yun Zhong reiterated a Buy...
-
Allergan Considering All Strategic Options 'With A Sense Of Urgency'
Thursday, March 15, 2018 - 9:05am | 361Read More...Allergan plc Ordinary Shares (NYSE: AGN) continued its two-week, 16-percent rebound Wednesday, and RBC Capital Markets anticipates 28 percent of additional upside. The Rating Analyst Randall Stanicky maintained a Buy on Allergan with a $213 price target. The Thesis Management’s afternoon...
-
RBC: Perrigo's Near-Term Risk Lessens, But Long-Term Issues Persist
Friday, November 10, 2017 - 3:22pm | 468Read More...Perrigo Company plc Ordinary Shares (NYSE: PRGO) impressed investors with third-quarter earnings Thursday and issued encouraging guidance that led some of Wall Street's bears to revisit their thesis on the pharmaceutical manufacturer. The Analyst RBC Capital Markets' Randall...
-
Allergan Now Trades Cheaper Than Its Standalone Value
Tuesday, April 5, 2016 - 11:07am | 756Read More...Shibani Malhotra of Nomura thinks Allergan plc Ordinary Shares (NYSE: AGN) is compelling, despite treasury notice that threatens the company's $160 billion merger with Pfizer Inc. (NYSE: PFE). Allergan shares fell as much as 20 percent amid fears that the U.S. Treasury Department and the...
-
Meeting With Mylan Management Shows This Is The Stock's Biggest Problem
Tuesday, February 16, 2016 - 10:25am | 298Read More...Mylan NV (NASDAQ: MYL) shares have lost 27 percent since February 8. RBC Capital Markets’ Randall Stanicky maintained a Sector Perform rating for the company, with a price target of $58. Although Mylan’s stock is inexpensive, there are few catalysts to drive upside, Stanicky...
-
Mylan And Teva Earnings Are Coming: Here's What To Expect
Monday, February 8, 2016 - 4:35pm | 251Read More...RBC Capital Markets on Monday issued a note on the specialty pharma space highlighting Mylan NV (NASDAQ: MYL) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) ahead of the companies' earnings announcements on Wednesday and Thursday, respectively. Analyst Randall Stanicky gave his opinion...
-
RBC Analyst Says 'Buy The Spread' On Allergan-Pfizer Deal
Monday, February 8, 2016 - 10:12am | 342Read More...Allergan plc Ordinary Shares (NYSE: AGN) have been volatile in recent months and are down 15 percent since August 10. RBC Capital Markets’ Randall Stanicky maintained an Outperform rating for the company, with a price target of $354. Tax experts suggest that there are little chances...
-
RBC: Neos Therapeutics Has 70% Upside, $500 Million Opportunity
Monday, August 17, 2015 - 9:58am | 249Read More...RBC Capital Markets analyst Randall Stanicky initiated Neos Therapeutics Inc (NASDAQ: NEOS) at an Outperform with a $35 price target – 70 percent above Friday's $20.63 closing price. Stanicky pointed to "bullish feedback from our physician survey" that suggests that the...
-
Depomed Rejected Horizon Pharma's Takeout Bid, But Still Trades As If M&A Is Happening
Thursday, July 30, 2015 - 8:07am | 243Read More...In a report published Thursday, RBC Capital analyst Randall Stanicky downgraded the rating on Depomed Inc (NASDAQ: DEPO) from Outperform to Sector Perform, while raising the price target from $26 to $32. While the company reported strong Q2 results and raised its 2015 guidance, Depomed also...
-
RBC Says Stay Away From Mylan, Perrigo; Go Long Teva, Allergan
Wednesday, July 29, 2015 - 8:54am | 351Read More...RBC Capital Markets released a new report this week detailing its updated take on the specialty pharmaceuticals sector following the announcement of Teva Pharmaceuticals (NYSE: TEVA)’s buyout of Allergan Plc (NYSE: AGN). Analyst Randall Stanicky revisited several companies in the sector...
-
RBC Capital Downgrades Allergan, But Still Keeps It As 'Core' Holding
Friday, July 17, 2015 - 8:10am | 256Read More...In a report published Friday, RBC Capital analyst Randall Stanicky downgraded the rating on Allergan PLC (NYSE: AGN) from Top Pick to Outperform, while maintaining a price target of $361. The analyst believes that there are few catalysts for the stock, with limited near-term P&L upside. "...
-
Eagle Pharma Has 'Several Upcoming Catalysts' And Is A Buy, RBC Says
Monday, June 22, 2015 - 3:58pm | 357Read More...Shares of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) continue to rise on Monday, as they have been doing since the beginning of the year. Earlier this morning, RBC Capital Markets analysts Randall Stanicky and James C Chen initiated coverage on the stock with an Outperform rating and a $97.00 price...
-
UPDATE: Canaccord Genuity Raises PT on Perrigo on Attractive Medium-Term Opportunities
Tuesday, July 9, 2013 - 3:03pm | 158Read More...In a report published Tuesday, Canaccord Genuity analyst Randall Stanicky raised the price target on Perrigo (NASDAQ: PRGO) from $128 to $140, reaffirming its Buy status. In the report, Canaccord Genuity observed, “While it feels like there has been more limited interest in the stock this year...
